Long-Term Outcomes of Permanent Cement Spacers in the Infected Foot

被引:14
作者
Elmarsafi, Tammer [1 ]
Oliver, Noah G. [1 ]
Steinberg, John S. [2 ]
Evans, Karen K. [2 ]
Attinger, Christopher E. [2 ]
Kim, Paul J. [2 ]
机构
[1] MedStar Georgetown Univ Hosp, Dept Plast Surg, Diabet Limb Salvage Fellow, Washington, DC USA
[2] MedStar Georgetown Univ Hosp, Dept Plast Surg, Washington, DC USA
关键词
amputation; bone cement; diabetes; infection; osteomyelitis; outcomes; BONE-CEMENT; VANCOMYCIN; GENTAMICIN; RISK;
D O I
10.1053/j.jfas.2016.10.022
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
When osteomyelitis occurs in the infected foot, cement spacers have been used as a limb salvage tool. The aim of the present study was to assess the longevity and outcomes in high-risk, low-demand patients who have undergone resection of bone and subsequent placement of permanent antibiotic-eluting cement spacers in the foot. A retrospective review case series of 30 patients who had undergone placement of a permanent antibiotic-eluting cement spacer in the foot were evaluated for retention, spacer exchange, removal, amputation, and functional status. The minimum follow-up time for inclusion was 12 months. Two thirds of all patients had successful spacers (n = 20) that were either retained (n = 14) or successfully exchanged (n = 6). One third of all patients experienced spacer failure (n = 10) and required removal. Of the 10 patients requiring spacer removal, 4 underwent removal with subsequent arthrodesis and 6 underwent removal with subsequent pseudoarthrosis. Also, 8 of these patients (26.7%) required partial foot amputation of the ipsilateral foot. These amputations were not directly related to the use or removal of the spacer. The average time to spacer removal or partial amputation was 20.9 (range 0.2 to 60.9) months. The longest retained spacer in the foot was 76 months at the last follow-up visit. The longest exchanged spacer at the last follow-up visit was 111 months. All surviving patients were ambulatory at the last follow-up visit. (C) 2016 by the American College of Foot and Ankle Surgeons. All rights reserved.
引用
收藏
页码:287 / 290
页数:4
相关论文
共 24 条
[1]   Elution of gentamicin and vancomycin from polymethylmethacrylate beads and hip spacers in vivo [J].
Anagnostakos, Konstantinos ;
Wilmes, Philippe ;
Schmitt, Eduard ;
Kelm, Jens .
ACTA ORTHOPAEDICA, 2009, 80 (02) :193-197
[2]   The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic [J].
Armstrong, DG ;
Todd, WF ;
Lavery, LA ;
Harkless, LB ;
Bushman, TR .
JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 1997, 87 (06) :272-278
[3]   Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot [J].
Berendt A.R. ;
Lipsky B. .
Current Diabetes Reports, 2004, 4 (6) :424-429
[4]   Temperature Evaluation During PMMA Screw Augmentation in Osteoporotic Bone-An In Vitro Study About the Risk of Thermal Necrosis in Human Femoral Heads [J].
Boner, Vanessa ;
Kuhn, Philipp ;
Mendel, Thomas ;
Gisep, Armando .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, 2009, 90B (02) :842-848
[5]   The global burden of diabetic foot disease [J].
Boulton, AJM ;
Vileikyte, L ;
Ragnarson-Tennvall, G ;
Apelqvist, J .
LANCET, 2005, 366 (9498) :1719-1724
[6]  
Burns Patrick R, 2008, Clin Podiatr Med Surg, V25, P95, DOI 10.1016/j.cpm.2007.10.008
[7]  
Cavanagh PR, 2000, DIABETES-METAB RES, V16, pS6, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR130>3.0.CO
[8]  
2-Z
[9]  
DiMaio FR, 2002, ORTHOPEDICS, V25, P1399
[10]   Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup [J].
Dubsky, Michal ;
Jirkovska, Alexandra ;
Bem, Robert ;
Fejfarova, Vladimira ;
Skibova, Jelena ;
Schaper, Nicolaas C. ;
Lipsky, Benjamin A. .
INTERNATIONAL WOUND JOURNAL, 2013, 10 (05) :555-561